Description
ASP2998 is an experimental drug being studied in clinical trials for various solid tumors, including colorectal cancer. It is being investigated as a potential treatment option, often in combination with standard therapies like pembrolizumab and carboplatin. The drug is being tested in early-phase trials (Phase 1) to determine its safety, find the right dosage, and see if it shows any signs of effectiveness against the tumor. These trials are primarily focused on safety but also aim to understand how the drug works in the body and its potential impact on the tumor and the immune system. ASP2998 is being studied in patients whose cancer has spread or returned after previous treatments.
Mechanism of Action
ASP2998 is designed to target a specific protein called TROP2, which is often found on the surface of certain cancer cells, including those in solid tumors. By attaching to TROP2, ASP2998 aims to deliver a therapeutic payload directly to the tumor cells, potentially leading to their destruction. The specific mechanism of action is being investigated in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.